CHANGZHOU, China, Nov. 29, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH) ("Kanghui" or the "Company"), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced the appointment of its independent directors, Mr. David Su, Ms. Patricia Peifen Chou and Ms. Shuchun Gao, as new members of its Compensation Committee pursuant to the board resolution resolved on November 9, 2011, with immediate effect. Concurrently, Mr. Su is appointed the Chairman of the Compensation Committee, while Mr. Libo Yang, Ms. Hongxin Nie and Mr. Suyang Zhang have resigned from the Compensation Committee.
Mr. Jiang Yikang, founder and Chairman of the Company, stated, "We are pleased with our continual efforts to achieve better corporate governance, as we now have both our Audit Committee and Compensation Committee fully comprised of independent directors. Our independent directors bring a great deal of experience and knowledge to our board, and we believe that under David's guidance, our new Compensation Committee would continue to achieve the optimal balance between creating fair incentives to attract and retain key talents and also enhancing shareholders' wealth."
About China Kanghui Holdings
Founded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma and spine. It has an extensive network of distributors for its products in China. In addition, Kanghui's products are distributed in 28 countries. Kanghui has strong research and development capabilities, focused on developing new proprietary products, including new product lines, extensions of existing product lines and enhancements of existing products. For more information, please visit www.kanghui.com.
Safe Harbor Statement
This press release contains forward-looking statements, including but not limited to the ability for the Compensation Committee of the Company to balance the Company's recruiting needs and the shareholders' interest'''. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations, market and operating conditions, estimates and projections about our industry, management's beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," "targets" and similar expressions, and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks and uncertainties beyond our control, which could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. Further information regarding these and other risks, uncertainties or factors is included in our filings with the U.S. Securities and Exchange Commission. We do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
China Kanghui Holdings Investor Relations Department
Asia Bridge Capital Limited
+86-186 1835 6339
SOURCE China Kanghui Holdings